Iida K, Kawai K, Hayashi H, Sekido N, Miyanaga N, Takeshima H, Akaza H
Dept. of Urology, University of Tsukuba.
Gan To Kagaku Ryoho. 1999 May;26(6):841-4.
We reported two cases of chemotherapy-refractory testicular cancer treated with all trans-retinoic acid (ATRA). Case 1. A 21-year-old male patient underwent salvage surgery for lung metastasis which had developed after treatment with three different cisplatin-based chemotherapy regimens for malignant teratoma. After recovery from surgery, he was treated with oral ATRA at daily dose 80 mg/m2 for four weeks. Case 2. A-45-year-old patient suffered from lung metastasis after orchiectomy for teratocarcinoma. The patient failed to achieve a complete response despite two different cisplatin-based chemotherapy and high dose chemotherapy regimens with bone marrow rescue. He was treated with oral ATRA for five weeks. Both patients showed disease progression with increase in tumor size and elevation of tumor marker during ATRA therapy. Side effects were acceptable except the headache in Case 2, who needed a dose reduction of ATRA. In conclusion, oral ATRA with this dose failed to show clinical antitumor activity in patients with refractory testicular cancer.
我们报告了两例用全反式维甲酸（ATRA）治疗化疗难治性睾丸癌的病例。病例1：一名21岁男性患者因恶性畸胎瘤接受了三种不同的含顺铂化疗方案治疗后出现肺转移，接受了挽救性手术。术后恢复后，他接受口服ATRA治疗，每日剂量80mg/m²，共四周。病例2：一名45岁患者因睾丸胚胎癌行睾丸切除术后出现肺转移。尽管接受了两种不同的含顺铂化疗方案以及联合骨髓救援的高剂量化疗方案，但该患者仍未获得完全缓解。他接受了口服ATRA治疗五周。两名患者在ATRA治疗期间均出现疾病进展，肿瘤大小增加且肿瘤标志物升高。除病例2出现头痛（需要减少ATRA剂量）外，副作用均可接受。总之，该剂量的口服ATRA在难治性睾丸癌患者中未显示出临床抗肿瘤活性。
